Scientists at the National Cancer Institute (NCI) developed a potent chimeric antigen receptor (CAR) targeting glypican-3 (GPC3). GPC3 is a cell surface proteoglycan preferentially expressed on Hepatocellular Carcinoma (HCC). The specific HN3 nanobody-IgG4H-CD28TM CAR included in this invention was much more potent both in in vitro cell models and in vivo mouse models. The NCI seeks licensing and/or co-development research collaborations for further development of the anti-GPC3 CAR to treat liver cancer.
Researchers at the National Cancer Institute developed a combination immunotherapy using Glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T cells and a recombinant IL-7 drug for the treatment of hepatocellular carcinoma (HCC).
The National Institute on Aging (NIA) seeks research licensees and/or co-development partners under a Cooperative Research and Development Agreement (CRADA) to advance preclinical and clinical development of repurposed compounds to treat Alzheimer’s disease.
Impairment of cell motility and membrane trafficking can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. Animal models that facilitate the study of roles of these proteins in vivo are therefore required. The National Cancer Institute (NCI) seeks licensees for Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking
The National Cancer Institute (NCI) developed Chimeric Antigen Receptors (CAR)-T Cells specifically targeting the unshed portion (“stalk”) of mesothelin in mesothelioma and other tumors. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these inventions for immunotherapy
Researchers at the National Cancer Institute (NCI) developed improved monospecific and bicistronic chimeric antigen receptors (CARs) targeting CD19 and CD20. Importantly, CD19 and CD20 are highly expressed in diffuse large B-cell lymphoma, acute lymphoblastic leukemia and other B-cell lymphomas. These improved CARs can be useful in treating these diseases. NCI is seeking parties interested in the co-development or licensing of this invention for immunotherapy.
The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of cyclic peptides or peptidomimetic molecules as potential non-hormonal contraceptives for males. The cyclic peptides disrupt spermatogenesis by inhibiting the phosphorylation of GRTH/DDX25 (gonadotropin-regulated testicular helicase).
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research licensees and /or co-development partners under a Cooperative Research and Development Agreement (CRADA) to advance preclinical and clinical development of methods to treat Alzheimer Disease using Carboxypeptidase E (CPE).
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a method of direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development and commercialization of small molecule inhibitors of the Eph receptor tyrosine kinase for Eph growth-dependent solid tumors such as colorectal cancer.
Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.
Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.
Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).
Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.
Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
The National Cancer Institute (NCI) has a novel mouse model of autoimmunity based on chronic interferon-gamma expression (ARE-Del). This mouse can be used as an in vivo model to study female-biased autoimmune diseases, including: Systemic Lupus Erythematosus, Primary Biliary Cholangitis, and Ovarian Failure Syndrome.
National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek licensees for a technology involving the preparation and use of personalized tumor vaccines for cancer immunotherapy employing a therapeutic strategy called MBTA. MBTA consists of vaccinations with irradiated tumor cells pulsed with phagocytic agonists (Mannan-BAM, a polysaccharide derivative of mannan), TLR (Toll-like receptor) ligands, and agonistic Anti-CD40-monoclonal antibody.
Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.